BioXcel Therapeutics (BTAI) provided an update on the progress of its late-stage clinical programs for lead neuroscience asset BXCL501, as well as its recent steps to enhance operational and financial flexibility and strengthen its Board leadership. BXCL501 Pivotal Phase 3 Trials: The majority of trial sites have been opened and patient enrollment is progressing with the SERENITY At-Home trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia. IGALMI Market Presence: The Company plans to continue to supply IGALMI to current and future customers through existing distribution channels, without commercial support. BXCL502 for Chronic Agitation in Alzheimer’s Disease: Continue to generate deeper mechanistic insights for BXCL502 in support of its potential to be developed for the treatment of chronic AAD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- BioXcel Therapeutics price target lowered to $3 from $5 at H.C. Wainwright
- Biotech Alert: Searches spiking for these stocks today
- Bioxcel Therapeutics Appoints Dr. Rajiv Patni to Board
- BioXcel Therapeutics files to sell 5.1M shares of common stock for holders
- Bioxcel Therapeutics Revises Executive Compensation Structure